Biogen (BIIB) has received a new Buy rating, initiated by Jefferies analyst, Andrew Tsai.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Tsai has given his Buy rating due to a combination of factors that suggest Biogen’s stock has potential for growth. One key element is the anticipated sales acceleration of Leqembi, a treatment for Alzheimer’s, particularly with the introduction of a more convenient at-home subcutaneous injection. This development is expected to drive significant revenue growth in 2026, alongside the potential for label expansion and emerging late-stage pipeline successes.
Additionally, Biogen’s stock is currently trading at a level that reflects a “no-pipeline” value, which means any positive developments in their product pipeline could lead to an upward movement in stock price. The company’s diversified late-stage pipeline, including promising treatments for Alzheimer’s, Parkinson’s, and autoimmune diseases, presents multiple growth opportunities. Despite some risks, such as competition in the Alzheimer’s market and potential biosimilar impacts, the overall risk/reward profile is viewed as favorable, supporting the Buy recommendation.
Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BIIB in relation to earlier this year.